{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:51:14Z","timestamp":1772135474447,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01205-7","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:05:47Z","timestamp":1765533947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term oral glucocerebrosidase activator reduces soluble \u03b1-synuclein oligomer accumulation in Parkinsonian LRRK2 mutant mouse brain"],"prefix":"10.1038","volume":"11","author":[{"given":"Zoe Yuen-Kiu","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice Eun-Seo","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley Yin-Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivy Lingyi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuefei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasine","family":"Malki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffi Xi-Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry Yupeng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson Wui-Man","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy Chun-Laam","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Leong","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip Wing-Lok","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"1205_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.exger.2014.09.014","volume":"68","author":"R Abdullah","year":"2015","unstructured":"Abdullah, R. et al. Parkinson\u2019s disease and age: the obvious but largely unexplored link. Exp. Gerontol. 68, 33\u201338 (2015).","journal-title":"Exp. Gerontol."},{"key":"1205_CR2","doi-asserted-by":"publisher","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","volume":"2","author":"C Klein","year":"2012","unstructured":"Klein, C. & Westenberger, A. Genetics of Parkinson\u2019s disease. Cold Spring Harb. Perspect. Med. 2, a008888 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1205_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1205_CR4","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/mds.28815","volume":"36","author":"D Ysselstein","year":"2021","unstructured":"Ysselstein, D. et al. Evaluation of strategies for measuring lysosomal glucocerebrosidase activity. Mov. Disord. 36, 2719\u20132730 (2021).","journal-title":"Mov. Disord."},{"key":"1205_CR5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","volume":"11","author":"ED Sidransky","year":"2012","unstructured":"Sidransky, E. D. & Lopez, G. M. D. The link between the GBA gene and Parkinsonism. Lancet Neurol. 11, 986\u2013998 (2012).","journal-title":"Lancet Neurol."},{"key":"1205_CR6","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuron.2019.12.004","volume":"105","author":"MX Henderson","year":"2020","unstructured":"Henderson, M. X. et al. Glucocerebrosidase activity modulates neuronal susceptibility to pathological \u03b1-synuclein insult. Neuron 105, 822\u2013836.e7 (2020).","journal-title":"Neuron"},{"key":"1205_CR7","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1371\/journal.pbio.0060006","volume":"6","author":"M Sandal","year":"2008","unstructured":"Sandal, M. et al. Conformational equilibria in monomeric \u03b1-synuclein at the single-molecule level. PLoS Biol. 6, e6\u20130108 (2008).","journal-title":"PLoS Biol."},{"key":"1205_CR8","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1038\/s41467-022-33252-6","volume":"13","author":"D Emin","year":"2022","unstructured":"Emin, D. et al. Small soluble \u03b1-synuclein aggregates are the toxic species in Parkinson\u2019s disease. Nat. Commun. 13, 5512\u20135512 (2022).","journal-title":"Nat. Commun."},{"key":"1205_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JPD-230065","volume":"13","author":"L Oftedal","year":"2023","unstructured":"Oftedal, L., Maple-Gr\u00f8dem, J., Tysnes, O.-B., Alves, G. & Lange, J. Seed amplification assay as a diagnostic tool in newly-diagnosed Parkinson\u2019s disease. J. Parkinson\u2019s. Dis. 13, 841\u2013844 (2023).","journal-title":"J. Parkinson\u2019s. Dis."},{"key":"1205_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12272-025-01538-0","volume":"48","author":"MM Alam","year":"2025","unstructured":"Alam, M. M., Lee, S. H., Wasim, S. & Lee, S.-Y. PET tracer development for imaging \u03b1-synucleinopathies: PET tracer development for imaging \u03b1-synucleinopathies. Arch. Pharmacal Res. 48, 333\u2013350 (2025).","journal-title":"Arch. Pharmacal Res."},{"key":"1205_CR11","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell 186, 3350\u20133367.e19 (2023).","journal-title":"Cell"},{"key":"1205_CR12","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo, H. et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112, 2540\u20132557.e8 (2024).","journal-title":"Neuron"},{"key":"1205_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","volume":"10","author":"H Sekiya","year":"2022","unstructured":"Sekiya, H. et al. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease. Acta Neuropathol. Commun. 10, 133\u2013133 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1205_CR14","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-019-13413-w","volume":"10","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein, D. et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat. Commun. 10, 5570\u20135579 (2019).","journal-title":"Nat. Commun."},{"key":"1205_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","volume":"45","author":"EM Rocha","year":"2022","unstructured":"Rocha, E. M., Keeney, M. T., Di Maio, R., De Miranda, B. R. & Greenamyre, J. T. LRRK2 and idiopathic Parkinson\u2019s disease. Trends Neurosci. 45, 224\u2013236 (2022).","journal-title":"Trends Neurosci."},{"key":"1205_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/mds.25462","volume":"28","author":"B Dehay","year":"2013","unstructured":"Dehay, B. et al. Lysosomal impairment in Parkinson\u2019s disease. Mov. Disord. 28, 725\u2013732 (2013).","journal-title":"Mov. Disord."},{"key":"1205_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00401-025-02871-w","volume":"149","author":"NM Jensen","year":"2025","unstructured":"Jensen, N. M. et al. Abundant non-inclusion \u03b1-synuclein pathology in Lewy body-negative LRRK2-mutant cases. Acta Neuropathol. 149, 41 (2025).","journal-title":"Acta Neuropathol."},{"key":"1205_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00401-025-02872-9","volume":"149","author":"H Sekiya","year":"2025","unstructured":"Sekiya, H. et al. Widespread distribution of \u03b1-synuclein oligomers in LRRK2-related Parkinson\u2019s disease. Acta Neuropathol. 149, 42 (2025).","journal-title":"Acta Neuropathol."},{"key":"1205_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","volume":"10","author":"D Chiasserini","year":"2015","unstructured":"Chiasserini, D. et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Mol. Neurodegener. 10, 15\u201315 (2015).","journal-title":"Mol. Neurodegener."},{"key":"1205_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41531-022-00354-3","volume":"8","author":"M Kedariti","year":"2022","unstructured":"Kedariti, M. et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 92 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1205_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41531-023-00517-w","volume":"9","author":"CEG Leyns","year":"2023","unstructured":"Leyns, C. E. G. et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 74 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1205_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin, S. et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 77, 427\u2013434 (2020).","journal-title":"JAMA Neurol."},{"key":"1205_CR23","doi-asserted-by":"publisher","first-page":"e2319336","DOI":"10.1001\/jamanetworkopen.2023.19336","volume":"6","author":"NJ Weinreb","year":"2023","unstructured":"Weinreb, N. J. & Goker-Alpan, O. Ambroxol as therapy for Gaucher disease\u2014ambitious but ambivalent. JAMA Netw. Open 6, e2319336\u2013e2319336 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1205_CR24","doi-asserted-by":"publisher","unstructured":"Migdalska-Richards, A., Ko, W. K. D., Li, Q., Bezard, E. & Schapira, A. H. V. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse. https:\/\/doi.org\/10.1002\/syn.21967 (2017).","DOI":"10.1002\/syn.21967"},{"key":"1205_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41531-022-00386-9","volume":"8","author":"PW-L Ho","year":"2022","unstructured":"Ho, P. W.-L. et al. Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain \u03b1-synuclein oligomers without adverse effects. NPJ Parkinson\u2019s. Dis. 8, 115\u2013115 (2022).","journal-title":"NPJ Parkinson\u2019s. Dis."},{"key":"1205_CR26","doi-asserted-by":"publisher","unstructured":"Lin, C. H. et al. Plasma pS129-alpha-synuclein is a surrogate biofluid marker of motor severity and progression in Parkinson\u2019s disease. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm8101601 (2019).","DOI":"10.3390\/jcm8101601"},{"key":"1205_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/15548627.2019.1603545","volume":"16","author":"PW-L Ho","year":"2020","unstructured":"Ho, P. W.-L. et al. Age-dependent accumulation of oligomeric SNCA\/\u03b1-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy 16, 347\u2013370 (2020).","journal-title":"Autophagy"},{"key":"1205_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep40887","volume":"7","author":"HF Liu","year":"2017","unstructured":"Liu, H. F. et al. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson\u2019s disease. Sci. Rep. 7, 40887 (2017).","journal-title":"Sci. Rep."},{"key":"1205_CR29","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1523\/JNEUROSCI.3809-03.2004","volume":"24","author":"HJ Lee","year":"2004","unstructured":"Lee, H. J., Khoshaghideh, F., Patel, S. & Lee, S. J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24, 1888\u20131896 (2004).","journal-title":"J. Neurosci."},{"key":"1205_CR30","first-page":"1","volume":"12","author":"MR Karim","year":"2025","unstructured":"Karim, M. R. et al. Internalized SNCA\/\u00e0-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade SNCA fibrils. Autophagy 12, 1\u201319 (2025).","journal-title":"Autophagy"},{"key":"1205_CR31","doi-asserted-by":"publisher","first-page":"e0252325","DOI":"10.1371\/journal.pone.0252325","volume":"16","author":"NK Polinski","year":"2021","unstructured":"Polinski, N. K. et al. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model. PLoS ONE 16, e0252325\u2013e0252325 (2021).","journal-title":"PLoS ONE"},{"key":"1205_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-023-00363-z","volume":"12","author":"A Drobny","year":"2023","unstructured":"Drobny, A. et al. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models. Transl. Neurodegener. 12, 31 (2023).","journal-title":"Transl. Neurodegener."},{"key":"1205_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","volume":"82","author":"G Ambrosi","year":"2015","unstructured":"Ambrosi, G. et al. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells. Neurobiol. Dis. 82, 235\u2013242 (2015).","journal-title":"Neurobiol. Dis."},{"key":"1205_CR34","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill, A. et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481\u20131495 (2014).","journal-title":"Brain"},{"key":"1205_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41531-022-00397-6","volume":"8","author":"A Navarro-Romero","year":"2022","unstructured":"Navarro-Romero, A. et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. NPJ Parkinson\u2019s. Dis. 8, 126\u2013126 (2022).","journal-title":"NPJ Parkinson\u2019s. Dis."},{"key":"1205_CR36","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy. Science 305, 1292\u20131295 (2004).","journal-title":"Science"},{"key":"1205_CR37","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.stemcr.2017.01.011","volume":"8","author":"S-Y Yang","year":"2017","unstructured":"Yang, S.-Y., Beavan, M., Chau, K.-Y., Taanman, J.-W. & Schapira, A. H. V. A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers. Stem Cell Rep. 8, 728\u2013742 (2017).","journal-title":"Stem Cell Rep."},{"key":"1205_CR38","doi-asserted-by":"publisher","first-page":"e0321145","DOI":"10.1371\/journal.pone.0321145","volume":"20","author":"T Okai","year":"2025","unstructured":"Okai, T. et al. AAV delivery of GBA1 suppresses \u03b1-synuclein accumulation in Parkinson\u2019s disease models and restores functions in Gaucher\u2019s disease models. PLoS ONE 20, e0321145 (2025).","journal-title":"PLoS ONE"},{"key":"1205_CR39","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s12035-018-1090-0","volume":"56","author":"TE Moors","year":"2019","unstructured":"Moors, T. E. et al. Characterization of brain lysosomal activities in GBA-related and sporadic parkinson\u2019s disease and dementia with Lewy bodies. Mol. Neurobiol. 56, 1344\u20131355 (2019).","journal-title":"Mol. Neurobiol."},{"key":"1205_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat. cell Biol. 4, 160\u2013164 (2002).","journal-title":"Nat. cell Biol."},{"key":"1205_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40478-017-0452-6","volume":"5","author":"S Arawaka","year":"2017","unstructured":"Arawaka, S., Sato, H., Sasaki, A., Koyama, S. & Kato, T. Mechanisms underlying extensive Ser129-phosphorylation in \u03b1-synuclein aggregates. Acta Neuropathol. Commun. 5, 48\u201348 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"1205_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","volume":"9","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam, N. et al. Dynamic physiological alpha-synuclein S129 phosphorylation is driven by neuronal activity. NPJ Parkinsons Dis. 9, 4 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1205_CR43","doi-asserted-by":"crossref","unstructured":"Kopytova, A. E. et al. Potential binding sites of pharmacological chaperone NCGC00241607 on mutant beta-glucocerebrosidase and its efficacy on patient-derived cell cultures in Gaucher and Parkinson\u2019s disease. Int. J. Mol. Sci. 24, 9105 (2023).","DOI":"10.3390\/ijms24109105"},{"key":"1205_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60134-4","volume":"16","author":"Dal","year":"2025","unstructured":"Dal et al. Developing nanobodies as allosteric molecular chaperones of glucocerebrosidase function. Nat. Commun. 16, 4890 (2025).","journal-title":"Nat. Commun."},{"key":"1205_CR45","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1021\/jacs.7b13003","volume":"140","author":"J Zheng","year":"2018","unstructured":"Zheng, J. et al. beta-glucocerebrosidase modulators promote dimerization of beta-glucocerebrosidase and reveal an allosteric binding site. J. Am. Chem. Soc. 140, 5914\u20135924 (2018).","journal-title":"J. Am. Chem. Soc."},{"key":"1205_CR46","doi-asserted-by":"publisher","unstructured":"Burbulla, L. F. et al. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aau6870 (2019).","DOI":"10.1126\/scitranslmed.aau6870"},{"key":"1205_CR47","unstructured":"Vanqua Bio. Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson\u2019s and Related Disorders. https:\/\/www.vanquabio.com\/vanqua-bio-announces-positive-interim-results-from-phase-1-clinical-trial-of-vq-101-an-orally-administered-brain-penetrant-allosteric-activator-of-gcase-for-the-treatment-of-gba-parkinsons\/ (2024)."},{"key":"1205_CR48","unstructured":"University College London. Ambroxol to Slow Progression in Parkinson Disease (ASPro-PD): A phase III multi-centre randomised placebo-controlled trial. https:\/\/www.ucl.ac.uk\/comprehensive-clinical-trials-unit\/research-projects\/2025\/mar\/aspro-pd (2025)."},{"key":"1205_CR49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2025.1687","volume":"82","author":"CRA Silveira","year":"2025","unstructured":"Silveira, C. R. A. et al. Ambroxol as a treatment for Parkinson disease dementia: a randomized clinical trial. JAMA Neurol. 82, 797\u2013807 (2025).","journal-title":"JAMA Neurol."},{"key":"1205_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/acn3.45","volume":"1","author":"HF Liu","year":"2014","unstructured":"Liu, H. F. et al. LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity. Ann. Clin. Transl. Neurol. 1, 199\u2013208 (2014).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1205_CR51","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","volume":"4","author":"M Malerba","year":"2008","unstructured":"Malerba, M. & Ragnoli, B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 4, 1119\u20131129 (2008).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1205_CR52","first-page":"281","volume":"21","author":"Y Tsunenari","year":"1981","unstructured":"Tsunenari, Y., Kast, A., Honma, M., Nishikawa, J. & Shibata, T. Toxicity studies with ambroxol (Na 872) in rats, mice and rabbits. Pharmacometrics 21, 281\u2013311 (1981).","journal-title":"Pharmacometrics"},{"key":"1205_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.mie.2016.09.052","volume":"587","author":"LS Frost","year":"2017","unstructured":"Frost, L. S., Dhingra, A., Reyes-Reveles, J. & Boesze-Battaglia, K. The use of DQ-BSA to monitor the turnover of autophagy-associated cargo. Methods Enzymol. 587, 43\u201354 (2017).","journal-title":"Methods Enzymol."},{"key":"1205_CR54","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00216-011-5496-z","volume":"402","author":"O Motabar","year":"2012","unstructured":"Motabar, O. et al. A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Anal. Bioanal. Chem. 402, 731\u2013739 (2012).","journal-title":"Anal. Bioanal. Chem."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01205-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01205-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:04:33Z","timestamp":1767020673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01205-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01205-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7185990\/v1","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests, and all authors have agreed to publish this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}